ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2265

Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients
Abstract Number: 0972

Prominent endothelial senescence in systemic sclerosis skin
Abstract Number: LB14

Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Abstract Number: 0185

Promoting Health Services Research Rigor and Reproducibility using CodeMapper: A novel tool for harmonization, collaboration, and precision
Abstract Number: 2235

Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study
Abstract Number: 0206

Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Abstract Number: 0032

Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease
Abstract Number: 1699

Protein-coding Somatic Genetic Variation in Lymphocytes in Systemic Lupus Erythematosus
Abstract Number: 1314

Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis
Abstract Number: 0112

Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis
Abstract Number: 1798

Proteomic Profiling of Chondrogenic Gene Therapy in Human MSCs Reveals Distinct Regenerative Pathways for Articular Cartilage Repair
Abstract Number: 0919

Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
Abstract Number: 1049

Provider Characteristics and Beliefs and Patient Factors Associated with Long-term Glucocorticoid Use in Patients with Rheumatoid Arthritis
Abstract Number: 2066

Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1185

Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].